Suchergebnisse - "Brauchle, Bettina"

PubPharm (13)

1

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

ErratumIn: Cancer Immunol Immunother. 2023 May 8;:. - PMID 37154851

2

Correction to : CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

ErratumFor: Cancer Immunol Immunother. 2023 Jul;72(7):2499-2512. - PMID 37041225

3

Correction to: CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

4

Correction to: CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

5

CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

6

CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

7

CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

8

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

enthalten in: Blood | 2022

von Philipp, N. | Kazerani, M. | Nicholls, A. | +22

CommentIn: Blood. 2022 Sep 8;140(10):1056-1058. - PMID 36074532

9

Augmenting bispecific T-cell engager (BiTE) therapy for the treatment of Acute Myeloid Leukemia

Erschienen: Dissertation, München, Ludwig-Maximilians-Universität, 2022

von Brauchle, B. | Subklewe, M.

10

A modular and controllable T cell therapy platform for acute myeloid leukemia

enthalten in: Leukemia | 2021

von Benmebarek, M. | Cadilha, B. | Herrmann, M. | +18